Enveric Biosciences (ENVB) news
Recent news
Enveric Biosciences secures new U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives in EVM401 series
Enveric Biosciences Inc. has received a U.S. patent allowance for a series of non-hallucinogenic mescaline derivatives under its EVM401 compound series, according to a recent filing with the U.S. Patent and Trademark Office [1]. The patent covers novel chemical modifications of mescaline, a…
AInvest Wire · Sep 15, 2026Enveric Biosciences shares rise 10% after selecting lead drug candidate
Enveric Biosciences shares rise 10% after selecting lead drug candidate Enveric Biosciences, a biotechnology company specializing in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, recently announced that they…
AInvest Wire · Dec 28, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.